For the second consecutive year, a company emerging from the Carlos Simon Foundation has secured funding under the European Innovation Council’s EIC Accelerator program, one of the most competitive deep-tech instruments in Europe.
Following the 2024 award to Premium Fertility, iPremom has now been selected to advance the clinical validation and regulatory development of its molecular diagnostic technology for early risk detection of preeclampsia.
The EIC Accelerator supports high-impact technologies grounded in scientific excellence and translational feasibility. The selection process involves multi-stage evaluation, assessing scientific robustness, technological maturity, implementation strategy, and market potential.
Together, the two awards represent close to €5 million in highly competitive European funding across consecutive funding cycles.
Premium Fertility is developing a medical device aimed at improving precision in embryo transfer during in vitro fertilization. iPremom is advancing a biomarker-based platform designed to enable earlier identification of women at increased risk of preeclampsia, a hypertensive disorder affecting approximately 5–8% of pregnancies worldwide and a major contributor to maternal and perinatal morbidity.
These consecutive recognitions highlight the Foundation’s structured approach to translational research in reproductive and maternal health, integrating scientific discovery with early validation, regulatory planning, and commercialization pathways.